Back to Search
Start Over
Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
- Source :
-
Transplantation proceedings [Transplant Proc] 2014 Sep; Vol. 46 (7), pp. 2308-11. - Publication Year :
- 2014
-
Abstract
- Background: Hepatitis B virus recurrence after liver transplantation (LT) has practically disappeared with a prophylaxis combining anti-hepatitis B surface antigen Immunoglobulins (HBIg) and antiviral drugs. Recently, cost-saving requirements pushed us to move from a fixed schedule of 50,000 IU intravenous HBIg in the first month after LT to an "on demand" administration guided by close monitoring of HBV surface antigen (HBsAg) and anti-HBV surface Antigen antibody (HBsAb) with a serological target of HBsAg negative and HBsAb>300 mIU/mL. In this context, we investigated the meaning of HBsAg quantitative determination at LT in predicting the need of HBIg in the first month after LT.<br />Methods: From February 2012 to July 2013, we performed 35 LTs in HBsAg-positive patients, 18 of whom had hepatitis Delta virus coinfection (Delta-positive). Anti-HBV prophylaxis was based on nucleos(t)ide analogues from day 1 post-LT and intravenous HBIg (10,000 IU intraoperatively and, in the following days, 5,000 IU and 2,500 IU pulses to reach and maintain the serological target).<br />Results: The HBsAg quantitative level at LT was significantly higher in Delta-positive recipients. Complete negativization of HBsAg and HBsAb serum level>300 mIU/mL was achieved on day 3 in Delta-positive and on day 2 in Delta-negative. A positive linear correlation between HBsAg quantitative level at LT and HBIg administered in the first month after LT was observed (RHO=.788), with a total of 32,500 IU HBIg used in HDV-positive and 22,000 IU in HDV-negative recipients (P=.0016). Compared to the old schedule, we saved a median of 14,750 IU in HDV-positive and 28,000 IU in Delta-negative. No HBV recurrence was observed in a median follow-up of 10.5 months.<br />Conclusions: Delta-positive patients need higher doses of HBIg to reach the serological target after LT because they have greater HBsAg quantitative levels at LT. In future studies, pre-LT HBsAg quantitative determination will be helpful to predict the actual need of HBIg early after LT.<br /> (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antiviral Agents therapeutic use
Biomarkers blood
Drug Therapy, Combination
Female
Hepatitis B diagnosis
Hepatitis B etiology
Hepatitis B immunology
Humans
Male
Middle Aged
Postoperative Complications diagnosis
Postoperative Complications immunology
Postoperative Complications virology
Recurrence
Treatment Outcome
Hepatitis B prevention & control
Hepatitis B Surface Antigens blood
Immunoglobulins therapeutic use
Immunoglobulins, Intravenous therapeutic use
Liver Transplantation
Postoperative Care methods
Postoperative Complications prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2623
- Volume :
- 46
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Transplantation proceedings
- Publication Type :
- Academic Journal
- Accession number :
- 25242775
- Full Text :
- https://doi.org/10.1016/j.transproceed.2014.07.043